Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$268.29
+0.9%
$259.57
$173.33
$276.47
$646.82B0.248.15 million shs1.47 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$10.06
+7.4%
$8.48
$6.20
$11.97
$1.65B2.474.67 million shs2.77 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$28.63
+0.6%
$25.62
$23.58
$29.09
$163.00B0.3441.62 million shs15.49 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-0.94%-2.68%+3.62%+19.19%+50.08%
Novavax, Inc. stock logo
NVAX
Novavax
+1.19%+5.76%+28.01%-8.23%+25.44%
Pfizer Inc. stock logo
PFE
Pfizer
+2.00%+1.94%+13.59%+11.59%+15.24%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$268.29
+0.9%
$259.57
$173.33
$276.47
$646.82B0.248.15 million shs1.47 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$10.06
+7.4%
$8.48
$6.20
$11.97
$1.65B2.474.67 million shs2.77 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$28.63
+0.6%
$25.62
$23.58
$29.09
$163.00B0.3441.62 million shs15.49 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-0.94%-2.68%+3.62%+19.19%+50.08%
Novavax, Inc. stock logo
NVAX
Novavax
+1.19%+5.76%+28.01%-8.23%+25.44%
Pfizer Inc. stock logo
PFE
Pfizer
+2.00%+1.94%+13.59%+11.59%+15.24%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.80
Moderate Buy$268.22-0.03% Downside
Novavax, Inc. stock logo
NVAX
Novavax
2.33
Hold$14.0039.14% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.28-1.23% Downside

Current Analyst Ratings Breakdown

Latest PFE, NVAX, and JNJ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/17/2026
Pfizer Inc. stock logo
PFE
Pfizer
DowngradeHold (C)Hold (C-)
8/7/2026
Pfizer Inc. stock logo
PFE
Pfizer
Lower Price TargetBuy$35.00 ➝ $31.00
8/6/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Boost Price TargetBuy$270.00 ➝ $287.00
8/6/2026
Novavax, Inc. stock logo
NVAX
Novavax
DowngradeStrong-BuyHold
8/4/2026
Novavax, Inc. stock logo
NVAX
Novavax
Reiterated RatingSell (D)
8/3/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingHold (C)
8/3/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Set Price Target$280.00
8/3/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Reiterated RatingBuy
8/3/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Boost Price TargetOverweight$272.00 ➝ $282.00
7/29/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Set Price Target$300.00
7/24/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
UpgradeBuy (B-)Buy (B)
(Data available from 9/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$94.19B6.86$14.14 per share18.98$33.85 per share7.93
Novavax, Inc. stock logo
NVAX
Novavax
$1.12B1.48$3.81 per share2.64($0.79) per share-12.74
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.61$4.50 per share6.36$15.26 per share1.88
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$8.6331.1020.962.5621.48%32.42%13.35%10/13/2026 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
$440.30M-$1.52N/AN/AN/A-59.87%-14.82%-13.35%11/5/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$0.7637.639.74N/A6.80%19.63%8.46%11/3/2026 (Estimated)

Latest PFE, NVAX, and JNJ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Novavax, Inc. stock logo
NVAX
Novavax
-$0.3798-$0.32+$0.0598-$0.32$52.51 million$56.70 million
8/4/2026Q2 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.6820$0.77+$0.0880-$0.04$14.40 billion$15.03 billion
7/15/2026Q2 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.84$2.90+$0.06$2.27$25.06 billion$25.31 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.362.00%+5.25%62.11%64 Years
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.01%-13.20%226.32%16 Years

Latest PFE, NVAX, and JNJ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/15/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.341.96%8/25/20268/25/20269/8/2026
6/24/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.01%7/24/20267/24/20269/1/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.44
1.09
0.81
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.33
2.30
Pfizer Inc. stock logo
PFE
Pfizer
0.71
1.27
0.96

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Novavax, Inc. stock logo
NVAX
Novavax
1.60%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.41 billionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990164.95 million162.31 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable

Recent News About These Companies

Pfizer (NYSE:PFE) Trading Up 2% - Time to Buy?
From Padcev to PF-08634404: Pfizer's Oncology Growth Push
3 Stocks for Investors Who Still Believe Cash Is King (PFE)
3 Stocks for Investors Who Still Believe Cash Is King (PFE)
Is Pfizer Stock Underperforming the S&P 500?
Pfizer Inc. $PFE Shares Bought by Sigma Planning Corp
Pfizer FY2026 EPS Estimate Increased by Erste Group Bank
Equities Analysts Issue Forecasts for Pfizer FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$268.29 +2.44 (+0.92%)
As of 11:25 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Novavax stock logo

Novavax NASDAQ:NVAX

$10.06 +0.69 (+7.39%)
As of 11:25 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Pfizer stock logo

Pfizer NYSE:PFE

$28.63 +0.17 (+0.59%)
As of 11:25 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.